Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis”), a global biopharmaceutical company focused on developing innovations for ophthalmic and neuro-ophthalmic diseases with significant unmet medical ...
The peer-reviewed publication this week in Nature Publishing Cell Death & Disease(1) provides compelling support for the hypothesis that iron dysregulation is not merely a bystander, but a potential ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback